03/16/2023

22nd Annual General Meeting of Shareholders Measures to Prevent the Spread of Covid 19

03/13/2023

Impacts of Silicon Valley Bank closure

03/02/2023

GNI Group summary Q&A from full-year 2022 financial results analyst call and other recent inquiries

01/13/2023

Resuming normal office operations

01/11/2023

2023 New Year Greeting

01/04/2023

FAQ for Our Disclosure on December 27, 2022, "GNI Group and Catalyst Biosciences Signed Agreements to Advance Liver Fibrosis Drug Development"

12/20/2022

Notice of COVID-19 infection of our employees and suspension of telephone reception

11/29/2022

FY2022 Q3 Analyst Call Q&A Summary

08/25/2022

FY2022 Q2 Analyst Call Q&A Summary

06/11/2022

Chief Scientific Officer of Cullgen Inc. will be speaking at the 30th Annual Meeting of the Japanese Breast Cancer Society

06/11/2022

Beijing Continent enrolls the first subject of pirfenidone capsules Phase III clinical trial for pneumoconiosis

05/24/2022

FY2022 Q1 Analyst Call Q&A Summary

04/15/2022

GNI Group FY2021 Annual General Meeting Q&A Summary

01/31/2022

Frequently Asked Questions Updated File (2022-JAN-31)

01/31/2022

Frequently Asked Questions Updated (2022-JAN-31)